Marcus V G Lacerda
Overview
Explore the profile of Marcus V G Lacerda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
2988
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Santos A, Brito M, Oliveira A, Davila R, Gama H, Silva E, et al.
Malar J
. 2024 Dec;
23(1):399.
PMID: 39716245
Background: To eliminate malaria by 2035, Brazil must address Plasmodium vivax. Previously, first-line treatment was chloroquine plus 7-day primaquine (PQ) without glucose-6-phosphate dehydrogenase (G6PD) deficiency testing. In 2021, point-of-care quantitative...
3.
Commons R, Rajasekhar M, Allen E, Yilma D, Chotsiri P, Abreha T, et al.
Lancet Child Adolesc Health
. 2024 Sep;
8(11):798-808.
PMID: 39332427
Background: Primaquine, the only widely available treatment to prevent relapsing Plasmodium vivax malaria, is produced as 15 mg tablets, and new paediatric formulations are being developed. To inform the optimal...
4.
Pittet L, Messina N, McDonald E, Orsini F, Barry S, Bonten M, et al.
EClinicalMedicine
. 2024 May;
72:102616.
PMID: 38774675
Background: Bacille Calmette-Guérin (BCG) vaccination has off-target (non-specific) effects that are associated with protection against unrelated infections and decreased all-cause mortality in infants. We aimed to determine whether BCG vaccination...
5.
Yakubu M, Mwangi V, Netto R, Alecrim M, Alves J, Almeida A, et al.
Sci Rep
. 2024 Mar;
14(1):7249.
PMID: 38538661
Malaria is the leading parasitic disease worldwide, with P. vivax being a major challenge for its control. Several studies have indicated metabolomics as a promising tool for combating the disease....
6.
Watson J, Commons R, Tarning J, Simpson J, Llanos Cuentas A, Lacerda M, et al.
Elife
. 2024 Feb;
13.
PMID: 38323801
In our recent paper on the clinical pharmacology of tafenoquine (Watson et al., 2022), we used all available individual patient pharmacometric data from the tafenoquine pre-registration clinical efficacy trials to...
7.
Pessoa R, Oliveira-Pessoa G, Souza B, Sampaio V, Pinto A, Barboza L, et al.
Sci Rep
. 2024 Jan;
14(1):1120.
PMID: 38212339
No abstract available.
8.
Price D, Nekkab N, Monteiro W, Villela D, Simpson J, Lacerda M, et al.
PLoS Med
. 2024 Jan;
21(1):e1004255.
PMID: 38194420
Background: Malaria transmission modelling has demonstrated the potential impact of semiquantitative glucose-6-phosphate dehydrogenase (G6PD) testing and treatment with single-dose tafenoquine for Plasmodium vivax radical cure but has not investigated the...
9.
Leite-Silva P, Pinheiro R, Barbosa-Ferreira J, Balieiro A, Sabido M, Lacerda M, et al.
Menopause
. 2023 Dec;
31(1):46-51.
PMID: 38113435
Objective: The aim of this study was to assess the prevalence of low bone mass (osteopenia/osteoporosis), the factors associated with low bone mass, and the risk of fractures in Brazilian...
10.
Mwangi V, Netto R, Borba M, Santos G, Lima G, Machado L, et al.
mSystems
. 2023 Oct;
8(6):e0072623.
PMID: 37874139
The SARS-CoV-2 virus infection in humans induces significant inflammatory and systemic reactions and complications of which corticosteroids like methylprednisolone have been recommended as treatment. Our understanding of the metabolic and...